Smith & Nephew New DYONICS(TM) RF System Enables Surgeons to Quickly and Precisely Remove Soft Tissue Using RF Energy
24 Februar 2010 - 1:35PM
PR Newswire (US)
ANDOVER, Mass., Feb. 24 /PRNewswire-FirstCall/ -- Smith &
Nephew's (NYSE: SNN)(LSE:SN) Endoscopy Division today announced the
launch of the DYONICS(TM) RF System, which incorporates a compact
generator with a family of probes for aggressively removing defects
and smoothing soft tissue during arthroscopic surgery. The system
complements Smith & Nephew Endoscopy's existing portfolio of
resection systems, which include the DYONICS POWER II Control
System for mechanical resection, and the VULCAN(TM) System for
specialized radiofrequency (RF) tissue removal. RF energy can
remove damaged soft tissue, coagulate bleeding vessels, smooth
rough cartilage, and shrink inflamed soft tissue in weight-bearing
joints such as the knee, shoulder and hip. "The DYONICS RF System
provides the control -- the power and the precision -- to
effectively remove tissue while eliminating bubbles, helping to
improve visualization during the procedure. Additionally, the
system is very easy to use," said Dr. Scott Trenhaile, MD, Clinical
Assistant Professor, University of Illinois College of Medicine at
Rockford. The system initially includes five specialized probes,
the most versatile of which is the DYONICS RF-S WHIRLWIND(TM) 90
degree Probe that is used to resect soft tissue and coagulate
bleeding vessels in the knee, shoulder and hip. The WHIRLWIND Probe
incorporates a high-flow suction feature to quickly pull bubbles
and free-floating debris from the procedure site, ensuring that the
surgeon has a clear view of the joint. Dr. Jose-Luis
Avila-Lafuente, Hospital MAZ, Shoulder and Elbow Surgery Unit,
Zaragoza, Spain was pleased with how fast and powerful the DYONICS
RF-S WHIRLWIND Probe was able to remove tissue. "The probe offers a
clear field of view and excellent coagulation capabilities," Dr.
Avila-Lafuente commented. "More importantly, what convinced me to
convert was the potential patient benefits. The new system produces
less heat than other systems while still providing the aggressive
tissue removal I need." "This self-contained DYONICS RF System is
compact and aggressive enough for both small clinics and large
medical facilities that perform multiple arthroscopy procedures
each day," said Courtney Manthei, associate market manager for
Resection at Smith & Nephew Endoscopy. "Surgeons who have used
this device in their procedures said they appreciate the control
that it provides, especially when working in difficult to reach
areas of the joint." Contact: Joe Metzger SVP, Corporate
Communications Smith & Nephew Endoscopy (978) 749-1330 About
Smith & Nephew Smith & Nephew is a global medical
technology business, specialising in Orthopaedic Reconstruction,
Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced
Wound Management products. Smith & Nephew is a global leader in
arthroscopy and advanced wound management and is one of the leading
global orthopaedics companies. Smith & Nephew is dedicated to
helping improve people's lives. The Company prides itself on the
strength of its relationships with its surgeons and professional
healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The Company
operates in 31 countries around the world. Annual sales in 2009
were $3.8 billion. This press release contains certain
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. In particular, statements
regarding planned growth in our business and in our operating
margins discussed under "Outlook" are forward-looking statements as
are discussions of our product pipeline. These statements, as well
as the phrases "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target",
"consider" and similar expressions, are generally intended to
identify forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors (including, but not limited to, the outcome of
litigation and regulatory approvals) that could cause the actual
results, performance or achievements of Smith & Nephew, or
industry results, to differ materially from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Please refer to the documents that
Smith & Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith & Nephew's most recent annual report
on Form 20F, for a discussion of certain of these factors. All
forward-looking statements in this press release are based on
information available to Smith & Nephew as of the date hereof.
All written or oral forward-looking statements attributable to
Smith & Nephew or any person acting on behalf of Smith &
Nephew are expressly qualified in their entirety by the foregoing.
Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement contained herein to reflect
any change in Smith & Nephew's expectation with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based. DATASOURCE: Smith & Nephew CONTACT:
Joe Metzger, SVP, Corporate Communications, Smith & Nephew
Endoscopy, +1-978-749-1330, Web Site: http://www.smith-nephew.com/
Copyright